A 83-01: Selective ALK-5 Inhibitor for Advanced TGF-β Pathway Research

Executive Summary: A 83-01 is a small-molecule inhibitor targeting ALK-5, ALK-4, and ALK-7, achieving an IC50 of ~12 nM for ALK-5 kinase inhibition in cellular assays (APExBIO). It suppresses Smad-dependent transcription downstream of TGF-β signaling, providing robust selectivity with minimal effect on BMP-induced pathways below 3 μM concentration. The compound is insoluble in water but highly soluble in DMSO (>21.1 mg/mL) and ethanol (>9.82 mg/mL), requiring storage at -20°C. A 83-01 is a standard reagent in epithelial-mesenchymal transition (EMT) research, cancer organoid modeling, and studies of fibrosis, with reproducible results in multiple preclinical models (Bioengineered 2021).

Biological Rationale

The transforming growth factor-beta (TGF-β) pathway is essential for cellular differentiation, proliferation, and tissue homeostasis. Dysregulation of TGF-β signaling is implicated in cancer progression, fibrosis, and organ development (Luo et al., 2021). ALK-5 (activin receptor-like kinase 5) is the canonical type I receptor mediating TGF-β signals, while ALK-4 and ALK-7 are involved in activin/nodal signaling. Inhibition of these kinases blocks downstream Smad2/3 phosphorylation, suppressing gene expression changes linked to epithelial-mesenchymal transition (EMT), tumor metastasis, and organoid self-renewal (A 83-01 in Dynamic Organoid Engineering). A 83-01, developed and provided by APExBIO, is a reference tool for dissecting these pathways.

Mechanism of Action of A 83-01

A 83-01 is a synthetic small molecule with the chemical name 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide (CAS: 909910-43-6; MW: 421.52). It binds competitively to the ATP-binding pocket of ALK-5, ALK-4, and ALK-7, preventing receptor-mediated phosphorylation of Smad2/3. In Mv1Lu cellular assays, A 83-01 inhibits TGF-β-induced luciferase reporter activity with an IC50 of approximately 12 nM and achieves 68% inhibition at 1 μM concentration. The compound exhibits minimal inhibition of BMP4-induced signaling in C2C12 cells at 1 μM but shows partial suppression above 3 μM. This selectivity enables researchers to isolate TGF-β/activin/nodal pathway effects from BMP-mediated processes (APExBIO).

Evidence & Benchmarks

• A 83-01 inhibits ALK-5/ALK-4/ALK-7 kinase activity in vitro with nanomolar potency (IC50 ~12 nM in Mv1Lu cells) (APExBIO).
• At 1 μM, A 83-01 achieves 68% inhibition of TGF-β-induced Smad-dependent luciferase activity in cell-based assays (APExBIO).
• No significant inhibition of BMP4-induced transcription at 1 μM in C2C12 cells; minor suppression observed only above 3 μM (APExBIO).
• TGF-β pathway inhibition by A 83-01 is used in organoid cultures to maintain epithelial identity and suppress fibroblast overgrowth (Luo et al., 2021).
• The compound is highly soluble in DMSO (>21.1 mg/mL) and ethanol (>9.82 mg/mL), with storage recommended at -20°C (APExBIO).
• A 83-01 enables robust, reproducible generation of human organoid models for cancer and fibrosis studies (A 83-01: Precision ALK-5 Inhibitor).

Applications, Limits & Misconceptions

A 83-01 is widely adopted in the following research contexts:

• Dissection of TGF-β/Smad signaling in EMT and organoid differentiation (A 83-01: Next-Generation ALK-5 Inhibitor). This article extends the mechanistic detail provided in previous work by quantifying selectivity and solubility parameters.
• Modeling cancer microenvironments and screening anti-fibrotic compounds (Luo et al., 2021).
• Maintaining epithelial cell fate in long-term human organoid cultures; preventing mesenchymal drift (A 83-01: Precision ALK-5 Inhibitor). This article clarifies how A 83-01's storage and solubility impact reproducibility in high-throughput settings.
• Pharmacokinetic and metabolic modeling of TGF-β pathway inhibitors (A 83-01 in Human Organoid Pharmacokinetics). This article contrasts recent findings on concentration-dependent selectivity.

Common Pitfalls or Misconceptions

• A 83-01 is not effective for inhibiting BMP-specific pathways at standard concentrations (≤1 μM); higher doses may induce off-target effects.
• The compound is insoluble in water; improper dissolution can lead to precipitation and variable bioactivity.
• Long-term storage of DMSO stock solutions at temperatures above -20°C may result in degradation.
• A 83-01 does not reverse established fibrosis or EMT phenotypes; it prevents pathway activation but does not revert terminal differentiation states.
• Some cell types may exhibit resistance due to alternate signaling or efflux mechanisms; dose-response should be empirically determined.

Workflow Integration & Parameters

A 83-01 is supplied by APExBIO as a solid compound, typically reconstituted in DMSO at concentrations up to 21.1 mg/mL. For maximal solubility, gentle warming and ultrasonic treatment in ethanol can achieve >9.82 mg/mL. Working concentrations in cell culture range from 0.1 to 3 μM, with higher doses reserved for specific screens. Solid material should be stored at -20°C; DMSO stock solutions are stable for several months at or below -20°C. For organoid and EMT studies, A 83-01 is added at the start of culture or upon medium change to selectively inhibit ALK-5/ALK-4/ALK-7 signaling (A 83-01 product page). Empirical titration is recommended due to cell line variability. Use of the A3133 kit ensures batch-to-batch reproducibility for high-throughput workflows.

Conclusion & Outlook

A 83-01 is a validated, selective TGF-β type I receptor inhibitor with robust performance in EMT, organoid modeling, and fibrosis studies. It delivers nanomolar potency, clear pathway specificity, and defined solubility/storage profiles. Ongoing work leverages A 83-01 for next-generation disease modeling and pharmacokinetic screening. As research demands increase for pathway precision and reproducibility, A 83-01—supplied by APExBIO—remains a cornerstone reagent for dissecting complex cellular signaling networks.